CTLA4 and non-small cell lung carcinoma: SU2C-NSCLC cohort data were curated from the original publication (18) and contained 153 patients treated with a PD-1 or PD-L1 inhibitor as monotherapy or in combination with a CTLA-4 inhibitor in the first-line/second-line (2L) setting.